TY - JOUR
T1 - Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer
T2 - Final results of a community-based observational Italian study
AU - Lutrino, Stefania Eufemia
AU - Bergamo, Francesca
AU - Schirripa, Marta
AU - Rosati, Gerardo
AU - Avallone, Antonio
AU - Giampieri, Riccardo
AU - Cordio, Stefano
AU - Berretta, Massimiliano
AU - Llimpe, Fabiola Rojas
AU - Pisa, Federica Edith
AU - Lonardi, Sara
AU - Loupakis, Fotios
AU - Fasola, Gianpiero
AU - Aprile, Giuseppe
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Background: Although the efficacy and safety of combining first-line chemotherapy with bevacizumab in elderly patients with colorectal cancer (CRC) is supported by the results of a phase III trial, real-practice data are limited. Patients and Methods: Our multi-center, community-based observational study included 233 elderly patients with CRC (median age=73 years, range=70-84 years). Baseline comorbidities and geriatric evaluation were also analyzed. Pre-specified end-points of the study were safety, tolerability and outcome results. Results: The incidence of both chemotherapy-induced and specific bevacizumab-related toxicities was low, and not influenced by baseline concurrent morbidities. Median progression free survival (PFS) and median overall survival (OS) were 9.9 months and 23.6 months, respectively. Fifty-six percent of patients received second-line chemotherapy. Conclusion: The upfront treatment of older patients with CRC with chemotherapy and bevacizumab is safe and efficacious in a real-world setting. No un expected toxicities were reported. Multi-dimensional geriatric evaluation is under-used in clinical practice.
AB - Background: Although the efficacy and safety of combining first-line chemotherapy with bevacizumab in elderly patients with colorectal cancer (CRC) is supported by the results of a phase III trial, real-practice data are limited. Patients and Methods: Our multi-center, community-based observational study included 233 elderly patients with CRC (median age=73 years, range=70-84 years). Baseline comorbidities and geriatric evaluation were also analyzed. Pre-specified end-points of the study were safety, tolerability and outcome results. Results: The incidence of both chemotherapy-induced and specific bevacizumab-related toxicities was low, and not influenced by baseline concurrent morbidities. Median progression free survival (PFS) and median overall survival (OS) were 9.9 months and 23.6 months, respectively. Fifty-six percent of patients received second-line chemotherapy. Conclusion: The upfront treatment of older patients with CRC with chemotherapy and bevacizumab is safe and efficacious in a real-world setting. No un expected toxicities were reported. Multi-dimensional geriatric evaluation is under-used in clinical practice.
KW - Advanced colorectal cancer
KW - Bevacizumab
KW - Italian study
KW - Older patients
UR - http://www.scopus.com/inward/record.url?scp=84928393962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928393962&partnerID=8YFLogxK
M3 - Article
C2 - 25862905
AN - SCOPUS:84928393962
VL - 35
SP - 2391
EP - 2399
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 4
ER -